302 Hospital of PLA&PLA Institute of Chinese Materia Medica, Beijing, China; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1348-56. doi: 10.1016/j.ejpb.2013.09.019. Epub 2013 Oct 5.
In this study, a novel orodispersible film (ODF) containing drug nanoparticles was developed with the goal of transforming drug nanosuspensions into a solid dosage form and enhancing oral bioavailability of drugs with poor water solubility. Nanosuspensions were prepared by high pressure homogenization and then transformed into ODF containing drug nanoparticles by mixing with hydroxypropyl methylcellulose solution containing microcrystalline cellulose, low substituted hydroxypropylcellulose and PEG-400 followed by film casting and drying. Herpetrione, a novel and potent antiviral agent with poor water solubility that extracted from Herpetospermum caudigerum, was chosen as a model drug and studied systematically. The uniformity of dosage units of the preparation was acceptable according to the criteria of Japanese Pharmacopoeia 15. The ODF was disintegrated in water within 30s with reconstituted nanosuspensions particle size of 280 ± 11 nm, which was similar to that of drug nanosuspensions, indicating a good redispersibility of the fast dissolving film. Result of X-ray diffraction showed that HPE in the ODF was in the amorphous state. In the in vitro dissolution test, the ODF containing HPE nanoparticles showed an increased dissolution velocity markedly. In the pharmacokinetics study in rats, compared to HPE coarse suspensions, the ODF containing HPE nanoparticles exhibited significant increase in AUC0-24h, Cmax and decrease in Tmax, MRT. The result revealed that the ODF containing drug nanoparticles may provide a potential opportunity in transforming drug nanosuspensions into a solid dosage form as well as enhancing the dissolution rate and oral bioavailability of poorly water-soluble drugs.
在这项研究中,开发了一种含有药物纳米颗粒的新型口腔分散片(ODF),旨在将药物纳米混悬剂转化为固体剂型,并提高水溶解度差的药物的口服生物利用度。纳米混悬剂通过高压匀质法制备,然后与含有微晶纤维素、低取代羟丙基纤维素和 PEG-400 的羟丙基甲基纤维素溶液混合,制成含有药物纳米颗粒的 ODF,再经过涂膜和干燥。从 Herpetospermum caudigerum 中提取的新型强效抗病毒药物 Herpetrione 具有较差的水溶性,被选为模型药物进行了系统研究。根据日本药典 15 的标准,该制剂的单位剂量均匀度可接受。ODF 在水中 30 秒内崩解,重构纳米混悬剂的粒径为 280±11nm,与药物纳米混悬剂相似,表明快速溶解膜具有良好的再分散性。X 射线衍射结果表明,ODF 中的 HPE 呈无定形状态。在体外溶出试验中,含 HPE 纳米颗粒的 ODF 显示出明显增加的溶出速度。在大鼠药代动力学研究中,与 HPE 粗混悬剂相比,含 HPE 纳米颗粒的 ODF 表现出 AUC0-24h、Cmax 的显著增加和 Tmax、MRT 的显著减少。结果表明,含药物纳米颗粒的 ODF 可能为将药物纳米混悬剂转化为固体剂型以及提高水溶解度差的药物的溶出率和口服生物利用度提供潜在机会。